Jesper Kjerulff leads again
PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.
Jesper has extensive knowledge and experience of working strategically and successfully with the drug development process from preclinical through phase I,II and III, on to registration and launch. Jesper has an intimate knowledge of the PN6047 project from his former role, and it will be a privilege for all of us at PharmNovo to have Jesper back in the team continuing the journey with PN6047.
Jesper Kjerulff leads again
PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.
Jesper has extensive knowledge and experience of working strategically and successfully with the drug development process from preclinical through phase I,II and III, on to registration and launch. Jesper has an intimate knowledge of the PN6047 project from his former role, and it will be a privilege for all of us at PharmNovo to have Jesper back in the team continuing the journey with PN6047.
Latest news
View all
Phase I study completed for PN6047
In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read more
PharmNovo presented at the BioStock Investor Meeting
PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read more
No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more